Corona Remedies Quarterly Results for Trading Insights
In Mar 2026, Corona Remedies (CORONA) reported revenue ₹358 Cr and net profit ₹45 Cr — revenue +21.4% YoY. Also explore CORONA price movement history to track price trends across different timeframes.
CORONA Quarterly Results — Revenue, Profit & EPS Highlights
Corona Remedies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit CORONA share price.
- Revenue of ₹358 Cr in Mar 2026 (-16.0% vs Jun 2026, +21.4% vs Mar 2025)
- Net Profit of ₹45 Cr in Mar 2026 (-25.0% vs Jun 2026, +40.6% vs Mar 2025)
- EBITDA of ₹66 Cr in Mar 2026 (-31.2% vs Jun 2026)
- Operating Margin of 18.0% in Mar 2026 (-4.0pp vs Jun 2026)
- Earnings Per Share of ₹7.41 in Mar 2026 (-24.6% vs Jun 2026)
Corona Remedies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
CORONA quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | Jun 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 358 | 426 | 364 | 295 | 349 | -16.0% | 21.4% |
| Net Profit (₹ Cr) | 45 | 60 | 52 | 32 | 46 | - | - |
| EBITDA (₹ Cr) | 66 | 96 | 81 | 56 | 72 | - | - |
| EPS (₹) | 7.41 | 9.83 | 8.55 | 5.16 | 7.55 | - | - |
| Operating Margin (%) | 18.0% | 22.0% | 22.0% | 18.0% | 20.0% | - | - |
CORONA Share Price Trend — 1-Year Movement Across Quarterly Results
Corona Remedies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Browse CORONA complete financial statements for revenue, profit, balance sheet and cash flow data.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
CORONA vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Corona Remedies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Mar 2026 |
₹463,071.60 Cr | 1875.1 | 15,018 | 2,710 | -5.6% | - | 18.0% | 165.9 |
|
Divis Laboratories
Mar 2026 |
₹225,157.18 Cr | 8588.0 | 2,986 | 751 | -5.0% | - | 25.2% | 303.4 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4971.0 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 431.9 |
|
Cipla
Mar 2026 |
₹117,137.57 Cr | 1431.1 | 6,612 | 543 | -9.3% | - | 8.2% | 208.3 |
|
Zydus Life Science
Mar 2026 |
₹113,855.38 Cr | 1115.6 | 7,569 | 1,341 | -4.3% | - | 17.7% | 88.2 |
All amounts in ₹ Crores